MDGL — MADRIGAL PHARMACEUTICALS, INC.

Nasdaq · Health Care · Pharmaceuticals · CIK 1157601 ·
Last close
$467.32
Market Cap
$10.80B
52W High
$569.44
52W Low
$445.20
ADV30
436,897
Next earnings
2026-07-30
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 364,252,000 324,245,000 -56,308,000 -57,939,000 1,244,645,000 292,726,000 720,921,000
Mar 2026 311,337,000 284,490,000 -92,723,000 -94,391,000 1,227,327,000 227,033,000 683,873,000
Dec 2025 321,083,000 296,635,000 -59,609,000 -58,575,000 1,259,589,000 198,693,000 656,900,000
Sep 2025 287,268,000 269,146,000 -113,975,000 -114,190,000 1,362,457,000 295,694,000 736,725,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-197,716,000
Investing CF
$46,970,000
Financing CF
$251,044,000
CapEx
$-8,297,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-12.89
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,242,796,000
Inventory
$99,391,000
Receivables
$192,311,000
ST Investments
$546,027,000
EBIT TTM
$-293,588,000
Pretax Income TTM
$-325,095,000
Interest Exp TTM
$31,507,000
Analysts
15

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,283,939,968
EBITDA
$-321,097,984
Free Cash Flow
$-80,466,248
Enterprise Value
$10,306,018,304
Total Cash
$838,753,024
Total Debt
$347,751,008
Shares Out
23,104,126
Trailing EPS
$-13.97
Book Value
$17.97
ROE
-53.3%
ROA
-17.8%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 958,403,000 -300,097,000 -288,284,000 1,259,589,000 656,900,000 -189,553,000
Dec 2024 180,133,000 -497,875,000 -465,892,000 1,042,247,000 287,864,000 -455,572,000
Dec 2023 0 -380,496,000 -373,630,000 640,547,000 235,214,000 -324,230,000
Dec 2022 0 -293,571,000 -295,350,000 362,572,000 165,183,000 -224,857,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$12.34

Max Pain — expiry 2026-12-18

max pain strike: $500.00 · spot: $467.32 · call oi: 2,616 · put oi: 1,489
Expected Move to 2026-12-18: ±$151.30 (32.38%) — implied range $316.02$618.62 · ATM straddle on $470.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ABVX Abivax S.A. $10.89B $124.92
CYTK CYTOKINETICS INC $10.47B $77.13
AXSM Axsome Therapeutics, Inc. $11.22B $217.99
SMMT Summit Therapeutics Inc. $10.39B $13.02
BMRN BIOMARIN PHARMACEUTICAL INC $11.60B $60.02

News headlines (Yahoo Finance, 1h cache)

Madrigal Pharmaceuticals (MDGL) Beat Earnings Estimates, Is It Still Below Fair Value?
2026-07-31 18:09 · Yahoo
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
2026-07-31 15:34 · Yahoo
Madrigal Pharmaceuticals Q2 Earnings Call Highlights
2026-07-30 18:04 · Yahoo
Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates
2026-07-30 12:35 · Yahoo
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
2026-07-30 11:00 · Yahoo
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
2026-07-29 22:25 · Yahoo
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
2026-07-27 14:38 · Yahoo
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2026-07-21 20:05 · Yahoo
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
2026-07-16 12:00 · Yahoo
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug
2026-07-13 23:47 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.